Related Experiment Video
Updated: Jul 11, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Progress on the road to new nerve agent treatments
1US Army Medical Research Institute of Chemical Defense, Biochemical Pharmacology Branch, Pharmacology Division, 3100 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, USA.
Journal of Applied Toxicology : JAT
|March 29, 2002
Summary
Despite 50 years of research, nerve agent treatments remain outdated. New scavenger prophylactics show promise for significantly reducing effective doses and enhancing protection against nerve agents.
Area of Science:
- Toxicology
- Pharmacology
- Chemical Warfare Defense
Background:
- Nerve agents pose a significant threat, with limited advancements in medical countermeasures over the past 50 years.
- Current treatments for nerve agent exposure have not substantially evolved since World War II.
Purpose of the Study:
- To analyze the reasons behind the stagnation in nerve agent treatment development.
- To propose novel strategies for improving prophylactic measures against nerve agents.
Main Methods:
- Review of historical and current nerve agent toxicity and treatment literature.
- Analysis of intrinsic challenges hindering therapeutic progress.
- Conceptualization of scavenger-based prophylactic agents.
Main Results:
- Identified critical limitations in current nerve agent treatment paradigms.
- Proposed the development of scavenger molecules as a novel prophylactic approach.
Conclusions:
- Scavenger prophylactics offer a promising strategy to significantly reduce the effective dose of nerve agents.
- This approach could provide protection against multiple times the lethal dose (LD50), enhancing individual resilience.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...